Contribution of the central histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol

The antipsychotic properties of haloperidol are primarily attributed to its ability to block dopamine D2 receptors. Histaminergic transmission modulates some of the behavioral effects of haloperidol. Hence, the present study investigated the contribution of central histaminergic transmission in the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacology, biochemistry and behavior biochemistry and behavior, 2015-12, Vol.139 (Pt A), p.59-66
Hauptverfasser: Jain, Nishant S., Tandi, Lakshyapati, Verma, Lokesh
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 66
container_issue Pt A
container_start_page 59
container_title Pharmacology, biochemistry and behavior
container_volume 139
creator Jain, Nishant S.
Tandi, Lakshyapati
Verma, Lokesh
description The antipsychotic properties of haloperidol are primarily attributed to its ability to block dopamine D2 receptors. Histaminergic transmission modulates some of the behavioral effects of haloperidol. Hence, the present study investigated the contribution of central histaminergic transmission in the cataleptic and neuroleptic effect of haloperidol respectively, using bar test and conditioned avoidance response (CAR) in a two-way shuttle box. The studies revealed that haloperidol (0.50 or 1mg/kg, i.p.) exhibited cataleptic behavior and inhibited conditioned avoidance response (CAR) in the doses 0.25 or 0.50mg in rats. The rats, pretreated centrally (i.c.v.) with histamine precursor, l-histidine (1, 2.5μg) or histamine neuronal inducer (H3 receptor antagonist), thioperamide (20, 50μg/rat), showed an enhanced cataleptic effect with sub-maximal dose of haloperidol (0.5mg/kg, i.p.). Similarly, the neuroleptic effect of haloperidol (0.25mg/kg, i.p.) in CAR was also potentiated in the rats pretreated with l-histidine (2.5μg) or thioperamide (50μg/rat). Further, the cataleptic effect of haloperidol (1mg/kg, i.p.) was attenuated in rats pretreated with the H1 receptor antagonist, chlorpheniramine (60, 80μg/rat, i.c.v.) or H2 receptor antagonist, ranitidine (60μg/rat, i.c.v.). However, the neuroleptic effect of haloperidol (0.5mg/kg, i.p.) was completely reversed by pretreatment with ranitidine (60μg/rat, i.c.v.), and partially attenuated by chlorpheniramine (80μg/rat, i.c.v.). These findings suggest the possible involvement of histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol probably via H1 or H2 receptor stimulation. •Contribution of histamine in the antipsychotic effect of haloperidol•Role of H1 or H2 receptor in the haloperidol induced catalepsy•Histamine stimulates H1 or H2 receptor to enhance haloperidol induced inhibition of CAR.
doi_str_mv 10.1016/j.pbb.2015.10.004
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1751213242</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091305715300769</els_id><sourcerecordid>1751213242</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-820d3fbfc42ecffbf2300bbe536102e3b7723031ca4123414c170bb63e08d64d3</originalsourceid><addsrcrecordid>eNqNkUFP3DAQhS0EKsvSH8AF5cglW4_txEE9oVULlVbqpZwtx5mwXmXt1HYq8e9xlKVHxMmeN988jeYRcgN0AxTqb4fN2LYbRqHK9YZScUZW0EheViDlOVlReg8lp5W8JFcxHmgmWC2_kEtWi6pi8n5F_Na7FGw7Jetd4fsi7bEwmDU9FHsbkz5ah-HFmiJLLh5tjDNp3ULqpAccU25r1xUOp-BPNfY9mhRnz70e_IjBdn64Jhe9HiJ-Pb1r8vzzx5_tU7n7_fhr-7ArDW_qVDaMdrxveyMYmj5_GKe0bbHiNVCGvJUyKxyMFsC4AGFA5n7NkTZdLTq-JneL7xj83wljUnlzg8OgHfopKpAVMOBMsE-gvBENqyjPKCyoCT7GgL0agz3q8KqAqjkSdVA5EjVHMkv54Hnm9mQ_tUfs_k-8Z5CB7wuA-R7_LAYVjUVnsLMhX1B13n5g_wbzBJ1t</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1738482503</pqid></control><display><type>article</type><title>Contribution of the central histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Jain, Nishant S. ; Tandi, Lakshyapati ; Verma, Lokesh</creator><creatorcontrib>Jain, Nishant S. ; Tandi, Lakshyapati ; Verma, Lokesh</creatorcontrib><description>The antipsychotic properties of haloperidol are primarily attributed to its ability to block dopamine D2 receptors. Histaminergic transmission modulates some of the behavioral effects of haloperidol. Hence, the present study investigated the contribution of central histaminergic transmission in the cataleptic and neuroleptic effect of haloperidol respectively, using bar test and conditioned avoidance response (CAR) in a two-way shuttle box. The studies revealed that haloperidol (0.50 or 1mg/kg, i.p.) exhibited cataleptic behavior and inhibited conditioned avoidance response (CAR) in the doses 0.25 or 0.50mg in rats. The rats, pretreated centrally (i.c.v.) with histamine precursor, l-histidine (1, 2.5μg) or histamine neuronal inducer (H3 receptor antagonist), thioperamide (20, 50μg/rat), showed an enhanced cataleptic effect with sub-maximal dose of haloperidol (0.5mg/kg, i.p.). Similarly, the neuroleptic effect of haloperidol (0.25mg/kg, i.p.) in CAR was also potentiated in the rats pretreated with l-histidine (2.5μg) or thioperamide (50μg/rat). Further, the cataleptic effect of haloperidol (1mg/kg, i.p.) was attenuated in rats pretreated with the H1 receptor antagonist, chlorpheniramine (60, 80μg/rat, i.c.v.) or H2 receptor antagonist, ranitidine (60μg/rat, i.c.v.). However, the neuroleptic effect of haloperidol (0.5mg/kg, i.p.) was completely reversed by pretreatment with ranitidine (60μg/rat, i.c.v.), and partially attenuated by chlorpheniramine (80μg/rat, i.c.v.). These findings suggest the possible involvement of histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol probably via H1 or H2 receptor stimulation. •Contribution of histamine in the antipsychotic effect of haloperidol•Role of H1 or H2 receptor in the haloperidol induced catalepsy•Histamine stimulates H1 or H2 receptor to enhance haloperidol induced inhibition of CAR.</description><identifier>ISSN: 0091-3057</identifier><identifier>EISSN: 1873-5177</identifier><identifier>DOI: 10.1016/j.pbb.2015.10.004</identifier><identifier>PMID: 26455279</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject><![CDATA[Animals ; Antipsychotic Agents - administration & dosage ; Antipsychotic Agents - pharmacology ; Antipsychotic effects ; Avoidance Learning - drug effects ; Catalepsy ; Catalepsy - chemically induced ; Catalepsy - drug therapy ; Catalepsy - metabolism ; Chlorpheniramine - administration & dosage ; Chlorpheniramine - pharmacology ; Conditioned avoidance chamber ; Dose-Response Relationship, Drug ; Drug Synergism ; Haloperidol ; Haloperidol - administration & dosage ; Haloperidol - pharmacology ; Histamine ; Histamine - metabolism ; Histamine Agonists - administration & dosage ; Histamine Agonists - pharmacology ; Histidine - administration & dosage ; Histidine - pharmacology ; Infusions, Intraventricular ; Male ; Neuroleptics ; Piperidines - administration & dosage ; Piperidines - pharmacology ; Ranitidine - administration & dosage ; Ranitidine - pharmacology ; Rats ; Receptors, Histamine - metabolism ; Synaptic Transmission - drug effects]]></subject><ispartof>Pharmacology, biochemistry and behavior, 2015-12, Vol.139 (Pt A), p.59-66</ispartof><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-820d3fbfc42ecffbf2300bbe536102e3b7723031ca4123414c170bb63e08d64d3</citedby><cites>FETCH-LOGICAL-c386t-820d3fbfc42ecffbf2300bbe536102e3b7723031ca4123414c170bb63e08d64d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0091305715300769$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26455279$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jain, Nishant S.</creatorcontrib><creatorcontrib>Tandi, Lakshyapati</creatorcontrib><creatorcontrib>Verma, Lokesh</creatorcontrib><title>Contribution of the central histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol</title><title>Pharmacology, biochemistry and behavior</title><addtitle>Pharmacol Biochem Behav</addtitle><description>The antipsychotic properties of haloperidol are primarily attributed to its ability to block dopamine D2 receptors. Histaminergic transmission modulates some of the behavioral effects of haloperidol. Hence, the present study investigated the contribution of central histaminergic transmission in the cataleptic and neuroleptic effect of haloperidol respectively, using bar test and conditioned avoidance response (CAR) in a two-way shuttle box. The studies revealed that haloperidol (0.50 or 1mg/kg, i.p.) exhibited cataleptic behavior and inhibited conditioned avoidance response (CAR) in the doses 0.25 or 0.50mg in rats. The rats, pretreated centrally (i.c.v.) with histamine precursor, l-histidine (1, 2.5μg) or histamine neuronal inducer (H3 receptor antagonist), thioperamide (20, 50μg/rat), showed an enhanced cataleptic effect with sub-maximal dose of haloperidol (0.5mg/kg, i.p.). Similarly, the neuroleptic effect of haloperidol (0.25mg/kg, i.p.) in CAR was also potentiated in the rats pretreated with l-histidine (2.5μg) or thioperamide (50μg/rat). Further, the cataleptic effect of haloperidol (1mg/kg, i.p.) was attenuated in rats pretreated with the H1 receptor antagonist, chlorpheniramine (60, 80μg/rat, i.c.v.) or H2 receptor antagonist, ranitidine (60μg/rat, i.c.v.). However, the neuroleptic effect of haloperidol (0.5mg/kg, i.p.) was completely reversed by pretreatment with ranitidine (60μg/rat, i.c.v.), and partially attenuated by chlorpheniramine (80μg/rat, i.c.v.). These findings suggest the possible involvement of histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol probably via H1 or H2 receptor stimulation. •Contribution of histamine in the antipsychotic effect of haloperidol•Role of H1 or H2 receptor in the haloperidol induced catalepsy•Histamine stimulates H1 or H2 receptor to enhance haloperidol induced inhibition of CAR.</description><subject>Animals</subject><subject>Antipsychotic Agents - administration &amp; dosage</subject><subject>Antipsychotic Agents - pharmacology</subject><subject>Antipsychotic effects</subject><subject>Avoidance Learning - drug effects</subject><subject>Catalepsy</subject><subject>Catalepsy - chemically induced</subject><subject>Catalepsy - drug therapy</subject><subject>Catalepsy - metabolism</subject><subject>Chlorpheniramine - administration &amp; dosage</subject><subject>Chlorpheniramine - pharmacology</subject><subject>Conditioned avoidance chamber</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Synergism</subject><subject>Haloperidol</subject><subject>Haloperidol - administration &amp; dosage</subject><subject>Haloperidol - pharmacology</subject><subject>Histamine</subject><subject>Histamine - metabolism</subject><subject>Histamine Agonists - administration &amp; dosage</subject><subject>Histamine Agonists - pharmacology</subject><subject>Histidine - administration &amp; dosage</subject><subject>Histidine - pharmacology</subject><subject>Infusions, Intraventricular</subject><subject>Male</subject><subject>Neuroleptics</subject><subject>Piperidines - administration &amp; dosage</subject><subject>Piperidines - pharmacology</subject><subject>Ranitidine - administration &amp; dosage</subject><subject>Ranitidine - pharmacology</subject><subject>Rats</subject><subject>Receptors, Histamine - metabolism</subject><subject>Synaptic Transmission - drug effects</subject><issn>0091-3057</issn><issn>1873-5177</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUFP3DAQhS0EKsvSH8AF5cglW4_txEE9oVULlVbqpZwtx5mwXmXt1HYq8e9xlKVHxMmeN988jeYRcgN0AxTqb4fN2LYbRqHK9YZScUZW0EheViDlOVlReg8lp5W8JFcxHmgmWC2_kEtWi6pi8n5F_Na7FGw7Jetd4fsi7bEwmDU9FHsbkz5ah-HFmiJLLh5tjDNp3ULqpAccU25r1xUOp-BPNfY9mhRnz70e_IjBdn64Jhe9HiJ-Pb1r8vzzx5_tU7n7_fhr-7ArDW_qVDaMdrxveyMYmj5_GKe0bbHiNVCGvJUyKxyMFsC4AGFA5n7NkTZdLTq-JneL7xj83wljUnlzg8OgHfopKpAVMOBMsE-gvBENqyjPKCyoCT7GgL0agz3q8KqAqjkSdVA5EjVHMkv54Hnm9mQ_tUfs_k-8Z5CB7wuA-R7_LAYVjUVnsLMhX1B13n5g_wbzBJ1t</recordid><startdate>201512</startdate><enddate>201512</enddate><creator>Jain, Nishant S.</creator><creator>Tandi, Lakshyapati</creator><creator>Verma, Lokesh</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QG</scope><scope>7TK</scope></search><sort><creationdate>201512</creationdate><title>Contribution of the central histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol</title><author>Jain, Nishant S. ; Tandi, Lakshyapati ; Verma, Lokesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-820d3fbfc42ecffbf2300bbe536102e3b7723031ca4123414c170bb63e08d64d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Antipsychotic Agents - administration &amp; dosage</topic><topic>Antipsychotic Agents - pharmacology</topic><topic>Antipsychotic effects</topic><topic>Avoidance Learning - drug effects</topic><topic>Catalepsy</topic><topic>Catalepsy - chemically induced</topic><topic>Catalepsy - drug therapy</topic><topic>Catalepsy - metabolism</topic><topic>Chlorpheniramine - administration &amp; dosage</topic><topic>Chlorpheniramine - pharmacology</topic><topic>Conditioned avoidance chamber</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Synergism</topic><topic>Haloperidol</topic><topic>Haloperidol - administration &amp; dosage</topic><topic>Haloperidol - pharmacology</topic><topic>Histamine</topic><topic>Histamine - metabolism</topic><topic>Histamine Agonists - administration &amp; dosage</topic><topic>Histamine Agonists - pharmacology</topic><topic>Histidine - administration &amp; dosage</topic><topic>Histidine - pharmacology</topic><topic>Infusions, Intraventricular</topic><topic>Male</topic><topic>Neuroleptics</topic><topic>Piperidines - administration &amp; dosage</topic><topic>Piperidines - pharmacology</topic><topic>Ranitidine - administration &amp; dosage</topic><topic>Ranitidine - pharmacology</topic><topic>Rats</topic><topic>Receptors, Histamine - metabolism</topic><topic>Synaptic Transmission - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jain, Nishant S.</creatorcontrib><creatorcontrib>Tandi, Lakshyapati</creatorcontrib><creatorcontrib>Verma, Lokesh</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Animal Behavior Abstracts</collection><collection>Neurosciences Abstracts</collection><jtitle>Pharmacology, biochemistry and behavior</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jain, Nishant S.</au><au>Tandi, Lakshyapati</au><au>Verma, Lokesh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Contribution of the central histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol</atitle><jtitle>Pharmacology, biochemistry and behavior</jtitle><addtitle>Pharmacol Biochem Behav</addtitle><date>2015-12</date><risdate>2015</risdate><volume>139</volume><issue>Pt A</issue><spage>59</spage><epage>66</epage><pages>59-66</pages><issn>0091-3057</issn><eissn>1873-5177</eissn><abstract>The antipsychotic properties of haloperidol are primarily attributed to its ability to block dopamine D2 receptors. Histaminergic transmission modulates some of the behavioral effects of haloperidol. Hence, the present study investigated the contribution of central histaminergic transmission in the cataleptic and neuroleptic effect of haloperidol respectively, using bar test and conditioned avoidance response (CAR) in a two-way shuttle box. The studies revealed that haloperidol (0.50 or 1mg/kg, i.p.) exhibited cataleptic behavior and inhibited conditioned avoidance response (CAR) in the doses 0.25 or 0.50mg in rats. The rats, pretreated centrally (i.c.v.) with histamine precursor, l-histidine (1, 2.5μg) or histamine neuronal inducer (H3 receptor antagonist), thioperamide (20, 50μg/rat), showed an enhanced cataleptic effect with sub-maximal dose of haloperidol (0.5mg/kg, i.p.). Similarly, the neuroleptic effect of haloperidol (0.25mg/kg, i.p.) in CAR was also potentiated in the rats pretreated with l-histidine (2.5μg) or thioperamide (50μg/rat). Further, the cataleptic effect of haloperidol (1mg/kg, i.p.) was attenuated in rats pretreated with the H1 receptor antagonist, chlorpheniramine (60, 80μg/rat, i.c.v.) or H2 receptor antagonist, ranitidine (60μg/rat, i.c.v.). However, the neuroleptic effect of haloperidol (0.5mg/kg, i.p.) was completely reversed by pretreatment with ranitidine (60μg/rat, i.c.v.), and partially attenuated by chlorpheniramine (80μg/rat, i.c.v.). These findings suggest the possible involvement of histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol probably via H1 or H2 receptor stimulation. •Contribution of histamine in the antipsychotic effect of haloperidol•Role of H1 or H2 receptor in the haloperidol induced catalepsy•Histamine stimulates H1 or H2 receptor to enhance haloperidol induced inhibition of CAR.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26455279</pmid><doi>10.1016/j.pbb.2015.10.004</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0091-3057
ispartof Pharmacology, biochemistry and behavior, 2015-12, Vol.139 (Pt A), p.59-66
issn 0091-3057
1873-5177
language eng
recordid cdi_proquest_miscellaneous_1751213242
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Animals
Antipsychotic Agents - administration & dosage
Antipsychotic Agents - pharmacology
Antipsychotic effects
Avoidance Learning - drug effects
Catalepsy
Catalepsy - chemically induced
Catalepsy - drug therapy
Catalepsy - metabolism
Chlorpheniramine - administration & dosage
Chlorpheniramine - pharmacology
Conditioned avoidance chamber
Dose-Response Relationship, Drug
Drug Synergism
Haloperidol
Haloperidol - administration & dosage
Haloperidol - pharmacology
Histamine
Histamine - metabolism
Histamine Agonists - administration & dosage
Histamine Agonists - pharmacology
Histidine - administration & dosage
Histidine - pharmacology
Infusions, Intraventricular
Male
Neuroleptics
Piperidines - administration & dosage
Piperidines - pharmacology
Ranitidine - administration & dosage
Ranitidine - pharmacology
Rats
Receptors, Histamine - metabolism
Synaptic Transmission - drug effects
title Contribution of the central histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T20%3A04%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Contribution%20of%20the%20central%20histaminergic%20transmission%20in%20the%20cataleptic%20and%20neuroleptic%20effects%20of%20haloperidol&rft.jtitle=Pharmacology,%20biochemistry%20and%20behavior&rft.au=Jain,%20Nishant%20S.&rft.date=2015-12&rft.volume=139&rft.issue=Pt%20A&rft.spage=59&rft.epage=66&rft.pages=59-66&rft.issn=0091-3057&rft.eissn=1873-5177&rft_id=info:doi/10.1016/j.pbb.2015.10.004&rft_dat=%3Cproquest_cross%3E1751213242%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1738482503&rft_id=info:pmid/26455279&rft_els_id=S0091305715300769&rfr_iscdi=true